earnings
confidence high
sentiment positive
materiality 0.75
Alnylam Q2 net product rev $672M (+64% YoY); TTR franchise $544M (+77%); raises FY guidance
ALNYLAM PHARMACEUTICALS, INC.
2025-Q2 EPS reported
-$0.95
revenue$1,367,878,000
- Q2 net product revenues $672M, +64% YoY; TTR franchise $544M (+77%) driven by AMVUTTRA sales of $492M.
- GAAP loss from operations $16M vs income $49M in Q2 2024; non-GAAP income from operations $95M.
- Raised FY2025 guidance: TTR revenue to $2.175-2.275B; total net product revenue to $2.65-2.8B (+27% at midpoint).
- ~1,400 ATTR-CM patients on AMVUTTRA as of June 30; approvals secured in EU, UK, Brazil, and Japan.
- Initiated TRITON-CM Phase 3 trial for nucresiran in ATTR-CM; received FDA Fast Track designation.